NOVA Novo Nordisk A/S ADS

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Novo Nordisk A/S and Encourages Investors with Losses to Contact the Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO). Investors who purchased or otherwise acquired Novo shares between February 5, 2015 and October 27, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 13, 2017 lead plaintiff deadline.

If you are a shareholder who suffered a loss during the Class Period, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, during the Class Period, Novo issued impressive revenue, operating profit, and sales growth information,

However, Novo was notified that its pricing model rendered unsustainable revenues, and its increased earnings and profit forecasts hid alleged difficulties.

When this information was revealed to investors, the value of Novo fell, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
11/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S ADS

Novo Nordisk A/S - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Novo Nordisk A/S: Key facts and statistics - LTM June 2025

A summary company profile, detailing Novo Nordisk A/S’s business operations and financial highlights.

Novo Nordisk A/S: Acquisition of Akero Therapeutics expands MASH pipel...

The debt-financed transaction will have only a limited effect on Novo Nordisk's leverage.

 PRESS RELEASE

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Be...

NEW YORK--(BUSINESS WIRE)-- , a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) and reminds investors of the March 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See . As detailed below, the complaint...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch